Table 4 Response rates, overall and by... | American Society of Hematology

Table 4

Response rates, overall and by dosing regimen

Response category	All patients (N = 64)	Receiving lower dosing regimens* (N = 35)	Receiving higher dosing regimens† (N = 29)
Response category	n (%)
ORR	30 (47)	13 (37)	17 (59)
CR	1 (1.6)	0	1 (3)
PR	25 (41)	11 (31)	14 (48)
MR‡	4 (6)	2 (6)	2 (7)
SD	25 (39)	16 (46)	9 (31)
PD	4 (6)	4 (11)	0
NE	5 (8)	2 (6)	3 (10)

Response category	All patients (N = 64)	Receiving lower dosing regimens* (N = 35)	Receiving higher dosing regimens† (N = 29)
Response category	n (%)
ORR	30 (47)	13 (37)	17 (59)
CR	1 (1.6)	0	1 (3)
PR	25 (41)	11 (31)	14 (48)
MR‡	4 (6)	2 (6)	2 (7)
SD	25 (39)	16 (46)	9 (31)
PD	4 (6)	4 (11)	0
NE	5 (8)	2 (6)	3 (10)

NE, not evaluable; SD, stable disease.

Dosing regimens include 150 mg BID for 21 d with 7 d off every 4 wk, or 150 mg QD, 50 mg BID, and 100 mg BID continuously.

Dosing regimens include 300 mg QD, 150 mg BID, 200 mg BID, and 350 mg BID continuously.

Category for WM only.